Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

A phase 1/2a trial of amsulostat, a novel pan-lysyl oxidase inhibitor, in patients with advanced myelofibrosis as an add-on to ruxolitinib treatment for up to 52 weeks

Ross Baker, Chih-Cheng Chen, Tsai-Yun Chen, Stanley Cheung, Hui-Hua Hsiao, Jae Hoon Lee, Ji Yun Lee, Sung-Eun Lee, Won Sik Lee, Lucia Masarova, Peter Tan, Shuhying Tan, Pankit Vachhani, Anne Marie Watson, Shang-Ju Wu, Jana Baskar, Joanna Leadbetter, Wolfgang Jarolimek

Blood (2025) 146 (Supplement 1): 2027.

https://doi.org/10.1182/blood-2025-2027

Published: 2025

Journal Articles

Pirtobrutinib vs ibrutinib in treatment-naïve and relapsed/refractory CLL/SLL: Results from the first randomized phase III study comparing a non-covalent and covalent BTK inhibitor

Blood (2025) 146 (Supplement 1): 683.

https://doi.org/10.1182/blood-2025-683

Published: 2025

Journal Articles

Evaluation of the novel TMPRSS6 antisense inhibitor sapablursen for treatment of polycythemia vera: Results of the imprssion clinical trial

Jeanne Palmer, Jonathan How, Prithviraj Bose, Pankit Vachhani, Adam Mead, Jonathan Sillar, Aaron Gerds, Angela Fleischman, Caitlin O'Neill, Ross Baker, Ronald Hoffman, Shiangtung Jung, Jon Ruckle, Keyvan Yousefi, Sanjay Bhanot, Terry Barrett, Ruben Mesa

Blood (2025) 146 (Supplement 1): 82.

https://doi.org/10.1182/blood-2025-82

Published: 2025

Journal Articles

Daratumumab monotherapy versus active monitoring in patients with high-risk smoldering multiple myeloma: Aquila outcomes based on mayo 2018/IMWG 2020 risk stratification, IMWG 2020 plus cytogenetic criteria, and age

Blood (2025) 146 (Supplement 1): 372.

https://doi.org/10.1182/blood-2025-372

Published: 2025

Journal Articles

Enhanced α2-3–linked sialylation determines the extended half-life of CHO-rVWF

Ciara Byrne, Soracha Ward, Jamie O’Sullivan, Alain Chion, Patricia Lopes, Bogdan Baci, Caoimhe Dowd, Darragh Jordan, Ross Baker, Roger J. S. Preston, Marco Monopoli, Peter L. Turecek, Maximilianos Kotsias, Jack Cheeseman, Alan B. Moran, Richard A. Gardner, Daniel I. R. Spencer, Ferdows Atiq, James S. O’Donnell

Blood (2025) 145 (23): 2768–2773.

https://doi.org/10.1182/blood.2024027038

Published: 2025

Includes: Supplemental data

Journal Articles

Multicenter, Open-Label Phase 1/2a Study of Pxs-5505 and Ruxolitinib in Patients with Primary, Post-Polycythemia Vera (PV) or Post-Essential Thrombocythemia (ET) Myelofibrosis

Peter Tan, Ross Baker, Sung-Eun Lee, Anne Marie Watson, Stanley Cheung, Shang-Ju Wu, Chih-Cheng Chen, Shuhying Tan, Pankit Vachhani, Tsai-Yun Chen, Jae Hoon Lee, Hui-Hua Hsiao, Ji Yun Lee, Won Sik Lee, Lucia Masarova, Jana Baskar, Wolfgang Jarolimek, Joanna Leadbetter

Blood (2024) 144 (Supplement 1): 1001.

https://doi.org/10.1182/blood-2024-204290

Published: 2024

Journal Articles

Mosunetuzumab Monotherapy Demonstrates Activity and a Manageable Safety Profile in Patients with Relapsed or Refractory Richter's Transformation

Chan Y. Cheah, Sarit Assouline, Ross Baker, Nancy L. Bartlett, Dima El-Sharkawi, Pratyush Giri, Matthew Ku, Stephen J. Schuster, Matthew Matasar, John Radford, Michael C. Wei, Shen Yin, Iris To, Jiangeng Huang, Antonia Kwan, L. Elizabeth Budde

Blood (2023) 142 (Supplement 1): 614.

https://doi.org/10.1182/blood-2023-173796

Published: 2023

Journal Articles

Age Regulates Desmopressin Responses in Patients with Low Von Willebrand Factor and Type 1 Von Willebrand Disease in the Lovic and Win Studies

Blood (2023) 142 (Supplement 1): 510.

https://doi.org/10.1182/blood-2023-184734

Published: 2023

Journal Articles

The Relationship between Low Von Willebrand Factor, Type 1 Von Willebrand Disease and Ageing - Novel Insights from the Lovic and Win Cohort Studies

Blood (2023) 142 (Supplement 1): 509.

https://doi.org/10.1182/blood-2023-181603

Published: 2023

Journal Articles

Isatuximab Plus Carfilzomib and Dexamethasone in Patients with Early Versus Late Relapsed Multiple Myeloma: Ikema Subgroup Analysis

Thierry Facon, Philippe Moreau, Ross Baker, Ludek Pour, Chang-Ki Min, Xavier Leleu, Mohamad Mohty, Lionel Karlin, Andreea Rawlings, Christina Tekle, Sandrine Schwab, Marie-Laure Risse, Thomas Martin

Blood (2022) 140 (Supplement 1): 1820–1822.

https://doi.org/10.1182/blood-2022-159105

Published: 2022

Journal Articles

Phase 1/2a Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of Pxs-5505 in Patients with Primary, Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis

Ross Baker, Jana Baskar, Brett Charlton, Gabriela S. Hobbs, Wolfgang Jarolimek, Sung-Eun Lee, Lucia Masarova, Anne-Marie Watson

Blood (2022) 140 (Supplement 1): 3947–3948.

https://doi.org/10.1182/blood-2022-158344

Published: 2022

Journal Articles

Updated Phase I/II Safety and Efficacy Results for Oral Bruton Tyrosine Kinase Inhibitor Rilzabrutinib in Patients with Relapsed/Refractory Immune Thrombocytopenia

Blood (2021) 138 (Supplement 1): 14.

https://doi.org/10.1182/blood-2021-145128

Published: 2021

Journal Articles

Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Patients with Renal Impairment: Ikema Subgroup Analysis

Marcelo Capra, MD PhD, Thomas Martin, III, MD, Philippe Moreau, MD, Ross Baker, MBBS, FRACP, FRCPA, BSc, Ludek Pour, MD, Chang-Ki Min, MD PhD, Xavier Leleu, MD, Mohamad Mohty, MD PhD, Marta Reinoso Segura, Mehmet Turgut, MD, Richard Leblanc, MD FRCPC, Marie-Laure Risse, Laure Malinge, Sandrine Schwab, Meletios A Dimopoulos

Blood (2020) 136 (Supplement 1): 46–47.

https://doi.org/10.1182/blood-2020-136415

Published: 2020

Journal Articles

Chronic Lymphocytic Leukaemia Is Associated with a Broad Platelet-Function Defect Which Is Exacerbated By Ibrutinib and Acalabrutinib

Scott R McGregor, BPharm, Grace Gilmore, Elizabeth E. Gardiner, PhD, Sarah Hicks, Shilpa Rakesh, Jim Tiao, Ross Baker, MBBS, FRACP, FRCPA, BSc

Blood (2018) 132 (Supplement 1): 3756.

https://doi.org/10.1182/blood-2018-99-120234

Published: 2018

Journal Articles

Hormonal Regulation of the Anticoagulant Protein S.

Quintin Hughes, BSc(hons), Janelle Staton, PhD, Mark Watson, PhD, Jennet Harvey, MBBS, FRCPA, Ross Baker, MBBS, FRACP, FRCPA

Blood (2005) 106 (11): 1934.

https://doi.org/10.1182/blood.V106.11.1934.1934

Published: 2005

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

A phase 1/2a trial of amsulostat, a novel pan-lysyl oxidase inhibitor, in patients with advanced myelofibrosis as an add-on to ruxolitinib treatment for up to 52 weeks

Pirtobrutinib vs ibrutinib in treatment-naïve and relapsed/refractory CLL/SLL: Results from the first randomized phase III study comparing a non-covalent and covalent BTK inhibitor

Evaluation of the novel TMPRSS6 antisense inhibitor sapablursen for treatment of polycythemia vera: Results of the imprssion clinical trial

Daratumumab monotherapy versus active monitoring in patients with high-risk smoldering multiple myeloma: Aquila outcomes based on mayo 2018/IMWG 2020 risk stratification, IMWG 2020 plus cytogenetic criteria, and age

Enhanced α2-3–linked sialylation determines the extended half-life of CHO-rVWF

Multicenter, Open-Label Phase 1/2a Study of Pxs-5505 and Ruxolitinib in Patients with Primary, Post-Polycythemia Vera (PV) or Post-Essential Thrombocythemia (ET) Myelofibrosis

Mosunetuzumab Monotherapy Demonstrates Activity and a Manageable Safety Profile in Patients with Relapsed or Refractory Richter's Transformation

Age Regulates Desmopressin Responses in Patients with Low Von Willebrand Factor and Type 1 Von Willebrand Disease in the Lovic and Win Studies

The Relationship between Low Von Willebrand Factor, Type 1 Von Willebrand Disease and Ageing - Novel Insights from the Lovic and Win Cohort Studies

Isatuximab Plus Carfilzomib and Dexamethasone in Patients with Early Versus Late Relapsed Multiple Myeloma: Ikema Subgroup Analysis

Phase 1/2a Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of Pxs-5505 in Patients with Primary, Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis

Updated Phase I/II Safety and Efficacy Results for Oral Bruton Tyrosine Kinase Inhibitor Rilzabrutinib in Patients with Relapsed/Refractory Immune Thrombocytopenia

Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Patients with Renal Impairment: Ikema Subgroup Analysis

Chronic Lymphocytic Leukaemia Is Associated with a Broad Platelet-Function Defect Which Is Exacerbated By Ibrutinib and Acalabrutinib

Hormonal Regulation of the Anticoagulant Protein S.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only